title: Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy.
authors.affiliation: Pediatric Department, University of Milano-Bicocca, San Gerardo Hospital, via Pergolesi 33, 20052 Monza, Italy. nicoletta.masera@pediatriamonza.it
authors.forename: N
authors.initials: N
authors.lastname: Masera
authors.forename: C
authors.initials: C
authors.lastname: Rescaldani
authors.forename: M
authors.initials: M
authors.lastname: Azzolini
authors.forename: C
authors.initials: C
authors.lastname: Vimercati
authors.forename: L
authors.initials: L
authors.lastname: Tavecchia
authors.forename: G
authors.initials: G
authors.lastname: Masera
authors.forename: V
authors.initials: V
authors.lastname: De Molfetta
authors.forename: P
authors.initials: P
authors.lastname: Arpa
mesh_terms: D000293:Adolescent; D000328:Adult; D001565:Benzoates / Q000009:adverse effects* / Q000627:therapeutic use; D002386:Cataract / Q000139:chemically induced*; D002648:Child; D002675:Child, Preschool; D000077588:Deferasirox; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007558:Italy; D013997:Time Factors; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use; D017086:beta-Thalassemia / Q000188:drug therapy*
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox